Heidemarie Kletzl
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial.
Journal: The Lancet. Child & adolescent health
Published: January 28, 2026
Risdiplam in Presymptomatic Spinal Muscular Atrophy.
Journal: The New England journal of medicine
Published: August 13, 2025
Further Comments on Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy. Reply.
Journal: The New England journal of medicine
Published: July 02, 2025
Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy.
Journal: The New England journal of medicine
Published: February 19, 2025
Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study.
Journal: Journal of neurology
Published: October 26, 2024
Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study.
Journal: Annals of clinical and translational neurology
Published: August 01, 2024
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam.
Journal: Journal of neurology
Published: January 26, 2024
Estimating drug concentration-response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes.
Journal: Statistical methods in medical research
Published: November 15, 2023
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study.
Journal: Neurology and therapy
Published: July 03, 2023
Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA).
Journal: Journal of neurology
Published: April 18, 2023
Last Updated: 09/26/2026